Our previous study demonstrated that cytoplasmic GPER in CAFs reduced breast cancer cell drug sensitivities to TAM, Herceptin, or epirubicin by providing tumour cells with lactate and pyruvate.20 Here, GPER1 is linked to breast cancer.